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Poster Session I S237Conclusion: Counts of T cells, B cells and myeloid DCs early
posttransplant depend on the number of these cells infused with
the graft. Naive T cell counts late posttransplant depend on
recipient age. GVHD appears to hamper the recovery of B cells,
regulatory NK cells and plasmacytoid DCs. Day 7 ATG serum
levels have a significant impact on T cell counts in the first 3
months posttransplant.226
KGF PROMOTES CD41 T CELL RECOVERY AFTER T-CELL DEPLETED
ALLOGENEIC HEMATOPOEITIC STEM CELL TRANSPLANTATION IN
PATIENTS CONDITIONED WITH TOTAL BODY IRRADIATION: IMPACT
ON OVERALL SURVIVAL
Goldberg, J.D.1, Zheng, J.2, Small, T.N.3, Castro-Malaspina, H.1,
Jakubowski, A.A.1, Heller, G.2, van den Brink, M.R.M.1, Perales, M.-A.1
1Memorial Sloan-Kettering Cancer Center, New York, NY; 2Memorial
Sloan-Kettering Cancer Center, New York, NY; 3Memorial
Sloan-Kettering Cancer Center, New York, NY
Delayed immune recovery (IR) after allogeneic HSCT (allo-
HSCT) is associated with increased risks of infection and relapse,
which can impact survival. Studies by others and us have shown in
pre-clinical mouse models that pre-HSCT administration of KGF
resulted in increased thymopoiesis and peripheral T-cell numbers
post allo-HSCT. Therefore, we performed a retrospective study to
evaluate the effect of KGF (Palifermin, Biovitrium) on IR in allo-
HSCT recipients. We conducted a review of 241 consecutive
patients who underwent an ablative T-cell depleted allo-HSCT
from 2005-2009. The conditioning regimen was TBI-based in 114
patients and chemotherapy-based in 127 patients. 160 patients
(66.4 %) received KGF peri-transplant. IR data (CD4, CD8, NK,
CD45RA, PHA response) were collected for one year after HSCT
and censored following DLI (n5 49), 2nd transplant (n5 21) or In-
terleukin 7 treatment (n5 8). A joint longitudinal survival model was
used to characterize the profile of IR data over time (longitudinal
model) and the association between immunologic data and survival
(survival model; overall survival (OS) and event-free survival
(EFS)). In the joint OSmodel analysis of TBI recipients, administra-
tion of KGF was marginally significantly associated with recovery of
CD4 count (slope 5 0.29, p 5 0.059) and there was a trend for an
association between CD4 recovery and OS (HR 5 0.69, p 5
0.077). With a similar association between administration of KGF
and recovery of CD4 count, CD4 recovery was not found to be asso-
ciated with EFS. For patients who received chemotherapy-based
preparative regimens, KGF had no impact on CD4 recovery.
However, in these patients, CD4 recovery was associated with an in-
creasedOS (HR5 0.61, p5 0.006) andEFS (HR5 0.56, p5 0.023).Table 1. Joint Longitudinal Survival Model
Regimen
Survival
Parameter
Longitudinal Model,
effect of KGF – CD4
Survival
Model – CD4
Slope (of log
transformed
CD4 count) 95% CI P-value HR 95% CI P-value
TBI OS 0.29 -0.010.59 0.059 0.69 0.461.04 0.077
TBI EFS 0.29 -0.020.60 0.063 0.69 0.411.17 0.171
Chemo OS NS NS NS 0.61 0.430.87 0.006
Chemo EFS NS NS NS 0.56 0.340.92 0.023For the combined group of patients, CD4 recovery was associated
with improvedOS (HR 0.65, p0.002), but not EFS; KGF did not im-
pact CD4 recovery. Administration of KGF did not impact the re-
covery of other immune subsets. This analysis is potentially
limited by its retrospective nature and the length of the study time
frame. However, our data suggest that KGF improves CD4 recovery
in recipients of TBI-based conditioning regimens, which in turn is
associated with increased OS. This data is consistent with the pre-
clinical data and clinical mucositis data suggesting the effect of
KGF may depend on the preparative regimen. A prospective trial
is warranted to further investigate these promising findings.227
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Introduction: T cell expression of PD-1, a marker of functional ex-
haustion manifested by inability to produce cytokines upon stimula-
tion, is upregulated in patients with acute graft-vs-host disease
(GHVD). This is thought to explain at least in part why patients
with acute GVHD have frequent infections. Here we wished to eval-
uate whether this is true also for chronic GVHD.
Patients and Methods: We studied 17 allogeneic hematopoietic
cell transplant recipients who have not developed acute or chronic
GVHD by day 84. Between day 84 and 365, 7 patients did and 10
patients did not develop chronic GVHD needing systemic immuno-
suppressive therapy (de novo, ie, without preceding acute GVHD).
We studied total CD4 and CD8 T cells as well as Epstein-Barr virus
(EBV)-specific CD4 andCD8T cells. Bloodmononuclear cells were
stimulated with EBV lysate or EBNA3A1B1C overlapping pep-
tides. After overnight incubation, expression of IFNg, TNFa, IL2
and PD-1 on CD31CD41CD8- or CD31CD4-CD81 cells was
determined by flow cytometry.
Results: PD-1 expression on total, EBV lysate-specific or EBNA3-
specific CD4 or CD8 T cells was not significantly higher among pa-
tients who did vs did not develop chronic GVHD. On the contrary,
there was a trend toward lower PD-1 expression on EBV lysate-spe-
cific CD4 and CD8 T cells and EBNA3-specific CD4 T cells in pa-
tients who developed chronic GVHD. This was significant (p\ .05,
Mann-Whitney test) for EBV lysate-specific CD4 T cells on day 84,
EBV lysate-specific CD8 T cells on day 180, EBV lysate-specific
CD4 and CD8 T cells on day 365, EBNA3-specific CD4 T cells on
day 84 and EBNA3-specific CD4 T cells on day 365. Consistent
with that, absolute counts of total, EBV lysate-specific or EBNA3-
specific T cells were not significantly lower in patients who did vs
did not develop chronic GVHD. On the contrary, there was a trend
toward higher EBV lysate-specific and EBNA3-specific CD4 or
CD8 T cell counts in patients who developed chronic GVHD. This
was significant on day 84 for total EBV lysate-specific CD4 and
CD8 cells, EBV lysate-specific CD41IFNg1 cells and CD81IFNg1
cells, and total EBNA3-specific CD4 cells, EBNA3-specific
CD41IFNg1 cells, CD41IL21 cells, CD41IFNg1TNFa1IL21
cells and CD81IFNg1 cells.
Conclusion: De novo chronic GvHD and its treatment do not ad-
versely affect the counts of functional T cells specific for EBV and,
perhaps, for persisting viruses in general.
